Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 2, 2019

View Archived Issues

Umbralisib plus ibrutinib demonstrate safety and activity in patients with leukemia and lymphoma

Methylscape alteration of DNA physicochemical properties can be applied for cancer diagnostic assays

Discovery of osimertinib analogue that selectively inhibits EGFR for NSCLC treatment

Novel selective azaindole TGF-beta receptor kinase inhibitors may improve immuno-oncology therapy

AOH-1160 demonstrates promising anticancer activity without significant toxicity in vivo

Sleeping sickness parasite can make its own sugar

Genetic diversity makes for better Alzheimer's model

ST-8116 demonstrates promising antitumor activity in preclinical models of colon cancer

Epigenetic analysis boosts malaria pathogenesis understanding

Patient enrollment ongoing in phase I study of BOS-172738

NicOx presents new compounds for eye disorders

Chiesi Farmaceutici patents new MAPK 14 inhibitors

Cadila Healthcare synthesizes NLRP3 inhibitors

Hanmi Science describes KDM1A inhibitors

Dosing begins in phase III study of Tyvyt for first-line esophageal squamous cell carcinoma

New PDE9 inhibitors presented by Merck & Co.

ALCAM-EGFR axis discovered as therapeutic target in multiple myeloma

BioCryst doses first patient in phase I trial of intravenous galidesivir

Cybrexa selects CBX-11 as lead clinical development candidate

Arcturus Therapeutics nominates ARCT-810 as development candidate for OTC deficiency

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...